Financial Digest

FDA’s OK Isn’t Always a Happy Day for Biotech Investors

  • 📰 WSJ
  • ⏱ Reading Time:
  • 15 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 9%
  • Publisher: 63%

Finance Finance Headlines News

Finance Finance Latest News,Finance Finance Headlines

Heard on the Street: Recent FDA approvals of drugs, such as Biogen’s Leqembi, have left investors unimpressed

Zack Wittman for The Wall Street Journal

Biotech companies often spend years—and millions of dollars—to develop a drug they hope will make it to market. If the day comes when their medicine finally gets regulatory approval, it is usually a cause for celebration by management and employees.Continue reading your article with

 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 98. in FİNANCE

Finance Finance Latest News, Finance Finance Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

FDA being asked to look into energy drink that has caffeine of 6 Coke cansBacked by two of YouTube’s best known stars, PRIME was an immediate sensation when it launched last year, prompting long lines in grocery stores and reports of school yard resale markets.
Source: PennLive - 🏆 463. / 53 Read more »